The goal of Siteman Cancer Center (SCC) Administration is to provide cutting edge research support for investigators, in order to facilitate development and growth of collaborative grants, clinical trials, and publications. SCC Administration supports the 270 SCC members, 8 research programs, 13 cores (11 full and two developing), and research working groups by providing: Administrative oversight of research programs and shared resources Administration of Research Development Award Program (seed grant mechanism) Administration of the SCC membership process Coordination of research seminars, workshops, and retreats Leadership or assistance in developing collaborations between investigators for new research initiatives Planning, coordination, and execution of multi-project research grants (e.g., SPOREs, PPGs) Targeted communication of cancer-related funding opportunities to SCC members Assistance for the SCC Director in recruitment of new faculty Development and management of computer databases and other information systems tools Fiscal management and consultation Space and equipment management Administrative leadership ofthe SCC strategic planning process Management ofthe Cancer Biology Pathway (doctoral training program) within the Division of Biology and Biomedical Sciences Administration of the SCC Summer Opportunities program SCC World Wide Web page development and maintenance

Public Health Relevance

Siteman Cancer Center Administration manages and facilitates the research of the only NCI Comprehensive Cancer Center in the state of Missouri and southern Illinois, with the goal to foster cutting edge, transdisciplinary science to reduce and ultimately eliminate the threat and impact of cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA091842-11S1
Application #
8530551
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-07-01
Budget End
2013-06-30
Support Year
11
Fiscal Year
2012
Total Cost
$2,779
Indirect Cost
$951
Name
Washington University
Department
Type
DUNS #
068552207
City
Saint Louis
State
MO
Country
United States
Zip Code
63130
Eberth, Jan M; Josey, Michele J; Mobley, Lee R et al. (2017) Who Performs Colonoscopy? Workforce Trends Over Space and Time. J Rural Health :
Kuroki, Lindsay M; Frolova, Antonina I; Wu, Ningying et al. (2017) Yield of Cytology Surveillance After High-Grade Vulvar Intraepithelial Neoplasia or Cancer. J Low Genit Tract Dis 21:193-197
Spencer, David H; Russler-Germain, David A; Ketkar, Shamika et al. (2017) CpG Island Hypermethylation Mediated by DNMT3A Is a Consequence of AML Progression. Cell 168:801-816.e13
Cusworth, Brian M; Krasnick, Bradley A; Nywening, Timothy M et al. (2017) Whipple-specific complications result in prolonged length of stay not accounted for in ACS-NSQIP Surgical Risk Calculator. HPB (Oxford) 19:147-153
Wang, Xuya; Mooradian, Arshag D; Erdmann-Gilmore, Petra et al. (2017) Breast tumors educate the proteome of stromal tissue in an individualized but coordinated manner. Sci Signal 10:
Knoop, Kathryn A; Gustafsson, Jenny K; McDonald, Keely G et al. (2017) Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria. Sci Immunol 2:
Tang, Rui; Habimana-Griffin, LeMoyne M; Lane, Daniel D et al. (2017) Nanophotosensitive drugs for light-based cancer therapy: what does the future hold? Nanomedicine (Lond) 12:1101-1105
Song, Hao; Ruan, Dan; Liu, Wenyang et al. (2017) Respiratory motion prediction and prospective correction for free-breathing arterial spin-labeled perfusion MRI of the kidneys. Med Phys 44:962-973
Bandyopadhyay, Shovik; Li, Junjie; Traer, Elie et al. (2017) Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia. PLoS One 12:e0179558
Lim, Kian-Huat; Langley, Emma; Gao, Feng et al. (2017) A clinically feasible multiplex proteomic immunoassay as a novel functional diagnostic for pancreatic ductal adenocarcinoma. Oncotarget 8:24250-24261

Showing the most recent 10 out of 1109 publications